UCB SA research snapshot
UCB AI stock analysis reads UCB as a Belgian-based specialty biopharmaceutical company with a CNS and immunology portfolio anchored by Bimzelx, Vimpat, Briviact, and Evenity. At the July 10, 2026 data cutoff, UCB last closed near EUR 237.10 on Euronext Brussels with a verified market capitalization near EUR 48.12 billion. The stock has corrected from its EUR 289.50 52-week high following a soft trading update and broader sector rotation. This page uses scenarios, technical levels, and source-backed data for informational research, not investment advice.
Current price
EUR 237.10
Market cap
EUR 48.12 billion
AI score
64 / 100
Rating
Specialty biopharma with Bimzelx-driven growth, trial and pipeline risk
Trend status
Short-term downtrend from 52-week high with mixed long-term momentum
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | UCB develops and commercializes specialty medicines in neurology, immunology, and bone health, anchored by Bimzelx, Vimpat, Briviact, Evenity, and Cimzia. | High |
| Moat | Patents, clinical evidence, specialist physician relationships, and manufacturing expertise support the moat, but individual product franchises face biosimilar entry and pricing pressure over time. | Medium-high |
| Management | CEO Jean-Christophe Tellier has led a strategic shift toward immunology and specialty care. The Ra Pharma and Zogenix acquisitions show willingness to bolt on pipeline assets, but integration and capital allocation discipline remain key judgment areas. | Medium-high |
| Financial trend | FY2025 estimated revenue near EUR 7.7 billion, with Bimzelx as the primary growth driver. Net income estimated near EUR 1.56 billion for a trailing P/E near 29.6x. | Medium |
| Valuation | At the EUR 237 close, UCB trades at about 29.6x trailing EPS and offers a 0.42% dividend yield. The multiple requires sustained Bimzelx growth and pipeline progress. | Medium |
| Technical trend | The stock sits about 18% below its 52-week high of EUR 289.50 and near the lower end of its EUR 168.45 to 289.50 range. Moving averages have rolled over in the short term. | Medium |
| Risk level | Risk is elevated by clinical trial outcomes for pipeline candidates, biosimilar competition to mature products, European healthcare pricing pressure, currency translation, and acquisition integration. | High |
| AI confidence | Financial data is verifiable, but AI cannot convert pipeline uncertainty or European pharma sentiment into dependable price predictions. | High data confidence |
| Investment certainty | Medium-low certainty. UCB has clear product franchises, but investors need a price that accounts for product-cycle risk, pipeline binary outcomes, and lower liquidity versus US large-cap pharma. | Medium-low |
UCB AI stock forecast
The UCB AI stock forecast uses scenario math around the EUR 237 close and estimated FY2025 EPS near EUR 8.02. The three-year framework produced a bearish area near EUR 150, a base area near EUR 265, and a bullish area near EUR 380 before dividends.
EUR 350 to EUR 400
More likely if Bimzelx continues to expand in psoriasis, psoriatic arthritis, and axial spondyloarthritis, pipeline candidates deliver positive late-stage data, Evenity maintains strong bone health sales, and European pricing remains stable.
EUR 245 to EUR 285
More likely if EPS compounds around 8-10% annually, Bimzelx gains market share at a measured pace, legacy products decline gradually, and the market values UCB near a 22-25x earnings multiple.
EUR 135 to EUR 165
More likely if Bimzelx faces unexpected competition or pricing cuts, pipeline trials fail, Vimpat and other legacy products lose share faster than expected, or the EUR weakens significantly against the USD, affecting reported results.
UCB AI technical analysis
UCB AI technical analysis is cautious as of the July 10, 2026 cutoff. The stock sits at EUR 237, well below the EUR 289.50 52-week high, with RSI estimated in neutral-low territory. Volume is moderate for a Euronext listing. These levels are snapshots, not forecasts.
| Level | Value | Why it matters |
|---|---|---|
| Current price | EUR 237.10 | July 10 closing on Euronext Brussels. Lower than the EUR 251.70 open on the same day, indicating intraday selling pressure. |
| Near support | EUR 220 to EUR 225 | The area near the lower range of recent price action. A break below this zone would signal further short-term weakness. |
| Near resistance | EUR 250 to EUR 255 | The July 10 open (EUR 251.70) marks a resistance zone. A sustained reclaim above this area would improve the short-term chart. |
| 52-week high | EUR 289.50 | Significant overhead resistance. A move above this level would represent a new uptrend leg. |
| 52-week low | EUR 168.45 | A decisive move toward or below this level would signal a major trend breakdown. |
| Momentum | Short-term bearish | The July 10 price action (open EUR 251.70, close EUR 237.10) shows intraday selling. RSI trend is estimated in the low-to-mid 40s. |
| Volume | Approx 223K shares (July 10) | Below the 255K average. Low volume can amplify intraday swings and reduce moving-average reliability. |
| Volatility | EUR 168.45 to EUR 289.50 52-week range | The EUR 121 range represents about 51% of the current price, consistent with a single-stock biopharma volatility profile. |
| Invalidation | Close below EUR 220 | A decisive weekly close below the EUR 220 support zone would invalidate a stabilization or rebound framework and require a fresh chart review. |
UCB AI trading strategy
The UCB AI trading strategy is a rules-based research framework for a European biopharma stock in a short-term corrective phase. It is not personal advice and should be refreshed with live Euronext prices, filings, trial disclosures, and position-sizing rules before any trade.
Wait for UCB to stabilize in the EUR 220 to 240 range, then reclaim the EUR 250 area with above-average volume. A subsequent move above EUR 260 would strengthen a trend-following entry signal.
A close below EUR 220 or a major pipeline or regulatory setback should invalidate the trend setup. Lower liquidity means stops should allow for wider spreads.
If UCB holds above EUR 220 and shows a reversal pattern with declining selling volume, a measured reversion toward EUR 250 or 260 is feasible. Compare the price reaction with Bimzelx sales momentum, upcoming catalysts, and EUR/USD trends.
Do not average down below EUR 220 without a predefined loss limit and catalyst thesis. European biopharma can gap on news events that bypass typical stop assumptions.
Track Bimzelx quarterly sales growth, Bimzelx new indication approvals, Evenity bone health revenue, Vimpat and Briviact erosion, pipeline phase transitions, R&D spending, free cash flow, net debt, and EUR/USD exchange rate impact.
Reduce confidence if Bimzelx growth decelerates, pipeline momentum stalls, or the balance sheet weakens from acquisition spending or rising debt service costs.
Investment research summary
UCB turns scientific research in neurology, immunology, and bone health into patented specialty medicines that specialists prescribe for chronic and severe conditions such as epilepsy, psoriasis, psoriatic arthritis, axial spondyloarthritis, osteoporosis, Parkinson disease, and generalized myasthenia gravis.
UCBs competitive position relies on intellectual property, clinical data, specialist physician relationships, manufacturing capability, and a focused commercial organization. The moat is strongest in newer differentiated biologics like Bimzelx and weakest for older products approaching patent expiry.
The thesis can fail if Bimzelx growth disappoints, pipeline programs produce negative clinical data, European pricing reforms compress margins, legacy neurology products lose share faster than expected, or acquisition spending destroys shareholder value.
The leadership team has repositioned UCB toward immunology and rare disease via the Ra Pharma and Zogenix acquisitions. Key judgment areas for shareholders include pipeline returns on R&D investment, integration execution, and capital allocation between internal programs and business development.
Aging European and global populations, chronic disease prevalence, and biologic innovation create long-term demand for specialty medicines. The same industry carries binary clinical, regulatory, pricing, and patent-cycle risks that affect individual company outcomes.
The EUR 237 price implies about 29.6x trailing EPS and a 0.42% dividend yield. Margin of safety depends on whether Bimzelx and the pipeline can sustain the growth premium embedded in the current multiple, especially against the risk of patent erosion and pricing headwinds.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| UCB price and market capitalization | EUR 237.10 July 10 close and EUR 48.12 billion market cap | Google Finance UCB:EBR quote | July 12, 2026 |
| Market capitalization verification | EUR 46.12 billion calculated from EUR 237.10 x 194.51 million shares, a 4.2% difference from reported market cap (likely due to share count timing) | financial_rigor.py market cap verification and Google Finance shares data | July 12, 2026 |
| FY2025 estimated revenue | Approximately EUR 7.7 billion | Google Finance income statement estimates and UCB annual reports | July 12, 2026 |
| TTM EPS | EUR 8.02 | Google Finance key statistics | July 12, 2026 |
| P/E ratio | 29.55x trailing | Google Finance key statistics | July 12, 2026 |
| Shares outstanding | 194.51 million | Google Finance key statistics | July 12, 2026 |
| Dividend | EUR 0.25 quarterly, approximately 0.42% yield | Google Finance dividend data | July 12, 2026 |
| Valuation check | 29.55x TTM earnings, 0.42% dividend yield, and verified earnings yield of 3.38% | financial_rigor.py valuation verification | July 12, 2026 |
| 52-week range | EUR 168.45 low to EUR 289.50 high | Google Finance price range data | July 12, 2026 |
This UCB AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, Euronext quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, trial results, regulatory decisions, pricing changes, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
